Ibrutinib in early stage CLL
Genetic testing may help doctors decide which early-stage CLL patients truly need ibrutinib treatment versus watchful waiting, personalizing care without overstating survival gains.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
The prognostic value of tumour budding for survival in stage II and…
Routine tumor budding assessment during colorectal cancer pathology could identify patients at higher risk who benefit most from added chemotherapy.
Promising but preliminaryAberrant splicing of MBD1 reshapes the epigenome to drive convergent…
A new RNA-based therapy targeting a common myelodysplasia mechanism restores blood cell production in patient samples, offering potential across multiple MDS subtypes.
Near-term implementable findingA randomized controlled trial comparing non-selective versus…
Risk-stratified thyroid biopsy selection improves detection of significant disease, though refinement is still needed before safely reducing unnecessary biopsies.
Promising but preliminaryExpression of the High Affinity Neurotensin Receptor Defines an…
Blocking a specific receptor on colorectal cancer cells may help immune cells infiltrate tumors, potentially enhancing checkpoint immunotherapy effectiveness.